Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael J Birrer

Showing results (101-110 of 222) with videos related to

Pageof 23
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 2, 2010
Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancerJunko Kikuchi, Ichiro Kinoshita, Yasushi Shimizu, et al.
Cancer|July 16, 2016
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerMarcela G Del Carmen, Jeff G Supko, Nora K Horick, et al.
Gynecologic Oncology|August 28, 2017
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineLainie P Martin, Jason A Konner, Kathleen N Moore, et al.
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Neoplasia (New York, N.Y.)|February 4, 2010
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalAdam Clauss, Vivian Ng, Joyce Liu, et al.
Oncogene|June 25, 2002
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialRamon G Manzano, Luis M Montuenga, Mark Dayton, et al.
Cancer Research|February 20, 2007
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinomaChunhua Lu, Tomas Bonome, Yang Li, et al.
Neoplasia (New York, N.Y.)|August 21, 2008
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancerDong Choon Park, Seung Geun Yeo, Mark R Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2012
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupKathryn Alsop, Sian Fereday, Cliff Meldrum, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 25, 2019
The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian CancerMatthew Schwede, Levi Waldron, Samuel C Mok, et al.
Pageof 23

Showing results (101-110 of 222) with videos related to

Sort By:
Pageof 23
Lung Cancer (Amsterdam, Netherlands)|October 2, 2010
Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancerJunko Kikuchi, Ichiro Kinoshita, Yasushi Shimizu, et al.
Cancer|July 16, 2016
Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancerMarcela G Del Carmen, Jeff G Supko, Nora K Horick, et al.
Gynecologic Oncology|August 28, 2017
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansineLainie P Martin, Jason A Konner, Kathleen N Moore, et al.
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Neoplasia (New York, N.Y.)|February 4, 2010
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survivalAdam Clauss, Vivian Ng, Joyce Liu, et al.
Oncogene|June 25, 2002
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialRamon G Manzano, Luis M Montuenga, Mark Dayton, et al.
Cancer Research|February 20, 2007
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinomaChunhua Lu, Tomas Bonome, Yang Li, et al.
Neoplasia (New York, N.Y.)|August 21, 2008
Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancerDong Choon Park, Seung Geun Yeo, Mark R Wilson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2012
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study GroupKathryn Alsop, Sian Fereday, Cliff Meldrum, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 25, 2019
The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian CancerMatthew Schwede, Levi Waldron, Samuel C Mok, et al.
Pageof 23